Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The dermatological treatment for reducing facial wrinkles with injectable drug Botulift
(botulinum toxin type A - Laboratório Químico Farmacêutico BergamoLtd.) has a not inferior
activity when compared with Botox ® (botulinum toxin - Allergan Inc.) in clinical trials.
Phase:
Phase 3
Details
Lead Sponsor:
Azidus Brasil
Collaborator:
Laboratório Químico Farmacêutico Bergamo Ltda.
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA